Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Fabrazyme manufacturing?Trintellix 20 mg cost?Cipla testosterone cypionate?Briviact prescription online?Insulin glargine cost?
See the DrugPatentWatch profile for Osimertinib
Osimertinib (brand name Tagrisso) received FDA approval in 2015, with the approval date of November 13, 2015. [1]
At launch, osimertinib was approved for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors had an EGFR T790M mutation and had progressed on or after EGFR TKI therapy. [1]
Different dates can appear depending on whether a source is reporting: - the original FDA approval date, or - later FDA label expansions or supplementary approvals after 2015. The original 2015 FDA approval date for osimertinib remains November 13, 2015. [1]
[1] https://www.drugs.com/approval_process/osimertinib.html
Other Questions About Osimertinib :